
Cardiol Therapeutics Inc
TSX:CRDL

Income Statement
Earnings Waterfall
Cardiol Therapeutics Inc
Revenue
|
0
CAD
|
Operating Expenses
|
-38.3m
CAD
|
Operating Income
|
-38.3m
CAD
|
Other Expenses
|
2.2m
CAD
|
Net Income
|
-36.1m
CAD
|
Income Statement
Cardiol Therapeutics Inc
Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | |||||||||||||||||||||||||||
Operating Expenses |
(3)
|
(5)
|
(7)
|
(10)
|
(13)
|
(14)
|
(14)
|
(14)
|
(14)
|
(14)
|
(21)
|
(27)
|
(30)
|
(35)
|
(39)
|
(40)
|
(42)
|
(45)
|
(41)
|
(39)
|
(36)
|
(31)
|
(30)
|
(30)
|
(32)
|
(38)
|
|
Selling, General & Administrative |
(2)
|
(3)
|
(5)
|
(8)
|
(10)
|
(11)
|
(10)
|
(10)
|
(10)
|
(10)
|
(10)
|
(14)
|
(15)
|
(21)
|
(28)
|
(27)
|
(28)
|
(28)
|
(22)
|
(20)
|
(18)
|
(15)
|
(15)
|
(17)
|
(19)
|
(24)
|
|
Research & Development |
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(3)
|
(4)
|
(4)
|
(4)
|
(4)
|
(11)
|
(13)
|
(14)
|
(15)
|
(11)
|
(12)
|
(14)
|
(17)
|
(19)
|
(19)
|
(18)
|
(16)
|
(14)
|
(13)
|
(13)
|
(14)
|
|
Depreciation & Amortization |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Operating Income |
(3)
N/A
|
(5)
-67%
|
(7)
-49%
|
(10)
-47%
|
(13)
-24%
|
(14)
-9%
|
(14)
0%
|
(14)
+3%
|
(14)
+1%
|
(14)
-6%
|
(21)
-44%
|
(27)
-29%
|
(29)
-11%
|
(35)
-20%
|
(39)
-10%
|
(39)
-2%
|
(42)
-7%
|
(45)
-7%
|
(41)
+9%
|
(39)
+5%
|
(36)
+7%
|
(31)
+15%
|
(30)
+3%
|
(30)
-2%
|
(32)
-5%
|
(38)
-20%
|
|
Pre-Tax Income | |||||||||||||||||||||||||||
Interest Income Expense |
(0)
|
(3)
|
(8)
|
(8)
|
(8)
|
(6)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
7
|
8
|
11
|
15
|
10
|
10
|
6
|
3
|
2
|
0
|
2
|
2
|
|
Non-Reccuring Items |
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(3)
N/A
|
(7)
-144%
|
(16)
-114%
|
(19)
-19%
|
(21)
-12%
|
(20)
+7%
|
(14)
+31%
|
(13)
+4%
|
(13)
+0%
|
(14)
-7%
|
(21)
-47%
|
(27)
-29%
|
(30)
-11%
|
(35)
-19%
|
(32)
+10%
|
(32)
0%
|
(32)
+0%
|
(30)
+6%
|
(31)
-4%
|
(29)
+6%
|
(30)
-3%
|
(28)
+7%
|
(28)
0%
|
(30)
-7%
|
(29)
+3%
|
(36)
-23%
|
|
Net Income | |||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(3)
|
(7)
|
(16)
|
(19)
|
(21)
|
(20)
|
(14)
|
(13)
|
(13)
|
(14)
|
(21)
|
(27)
|
(30)
|
(35)
|
(32)
|
(32)
|
(32)
|
(30)
|
(31)
|
(29)
|
(30)
|
(28)
|
(28)
|
(30)
|
(29)
|
(36)
|
|
Net Income (Common) |
(3)
N/A
|
(7)
-144%
|
(16)
-114%
|
(19)
-19%
|
(21)
-12%
|
(20)
+7%
|
(14)
+31%
|
(13)
+4%
|
(13)
+0%
|
(14)
-7%
|
(21)
-47%
|
(27)
-29%
|
(30)
-11%
|
(35)
-19%
|
(32)
+10%
|
(32)
0%
|
(32)
+0%
|
(30)
+6%
|
(31)
-4%
|
(29)
+6%
|
(30)
-3%
|
(28)
+7%
|
(28)
0%
|
(30)
-7%
|
(29)
+3%
|
(36)
-23%
|
|
EPS (Diluted) |
-0.2
N/A
|
-0.32
-60%
|
-0.62
-94%
|
-0.73
-18%
|
-0.81
-11%
|
-0.76
+6%
|
-0.53
+30%
|
-0.5
+6%
|
-0.49
+2%
|
-0.42
+14%
|
-0.69
-64%
|
-0.76
-10%
|
-0.61
+20%
|
-0.81
-33%
|
-0.73
+10%
|
-0.51
+30%
|
-0.51
N/A
|
-0.48
+6%
|
-0.49
-2%
|
-0.46
+6%
|
-0.48
-4%
|
-0.44
+8%
|
-0.44
N/A
|
-0.46
-5%
|
-0.44
+4%
|
-0.53
-20%
|